Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 10/20 | 0.69 |
| ▸ | OPRM1 | P35372 | 12/20 | 0.60 |
| ▸ | OPRK1 | P41145 | 10/20 | 0.60 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.53 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.53 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.53 |
| ▸ | MRGPRX2 | Q96LB1 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nicomorphine SCHEMBL680036 | 1.00 | OPRD1 (0.69) | OPRD1OPRM1OPRK1ADRB1PDE4D | |
| Nicomorphine SCHEMBL29408441 | 1.00 | OPRD1 (0.69) | OPRD1OPRM1OPRK1ADRB1PDE4D | |
| Nicomorphine SCHEMBL29349768 | 1.00 | OPRD1 (0.69) | OPRD1OPRM1OPRK1ADRB1PDE4D | |
| Nicomorphine SCHEMBL1649977 | 0.99 | OPRD1 (0.68) | OPRD1OPRM1OPRK1ADRB1PDE4D | |
| Nicomorphine SCHEMBL395672 | 0.99 | OPRD1 (0.68) | OPRD1OPRM1OPRK1ADRB1PDE4D | |
| Nicocodine SCHEMBL1023092 | 0.94 | OPRM1 (0.69) | OPRD1OPRM1OPRK1ADRB1PDE4D | |
| Nicocodine SCHEMBL159020 | 0.94 | OPRM1 (0.69) | OPRD1OPRM1OPRK1ADRB1PDE4D | |
| Nicocodine SCHEMBL29531263 | 0.94 | OPRM1 (0.69) | OPRD1OPRM1OPRK1ADRB1PDE4D | |
| SCHEMBL27496008 | 0.91 | OPRD1 (0.66) | OPRD1OPRM1OPRK1ADRB1PDE4D | |
| SCHEMBL1556900 | 0.91 | OPRD1 (0.82) | OPRD1OPRM1OPRK1ADRB1PDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 8824 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117064869-B | Capsule type inhalation powder spray and preparation method thereof | 山东京卫制药有限公司 | 2026-05-12 | — | — | CN | claimed |
| EP-4724049-A1 | MODIFIED RELEASE FILL COMPOSITIONS FOR DOSAGE FORMS AND METHODS OF PREPARATION AND USE THEREOF | Catalent Ontario Limited (CA) | 2026-04-15 | — | — | EP | claimed |
| EP-4714444-A1 | PREPARATION FOR AND USE OF CANNABIDIOL DERIVATIVE DRUGS | Changchun Institute Of Applied Chemistry Chinese Academy Of Sciences (CN) | 2026-03-25 | — | — | EP | claimed |
| US-20250319074-A1 | TREATMENT AND MANAGEMENT OF AUGMENTATION IN RESTLESS LEGS SYNDROME | UNIV EAST CAROLINA (US) | 2025-10-16 | — | — | US | claimed |
| US-20250255781-A1 | PROCESSES FOR PREPARATION OF 3-D PRINTED PHARMACEUTICAL PRODUCTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-08-14 | — | — | US | claimed |
| US-12383743-B2 | Treatment of addiction and dependency | TACA JR ARTURO C (US) | 2025-08-12 | — | — | US | claimed |
| US-20250228771-A1 | ALKALINE INTRAORAL PRODUCTS | EMPLICURE AB (publ) (SE) | 2025-07-17 | — | — | US | claimed |
| EP-4581017-A1 | NEW N-HETEROARYLBENZAMIDES DERIVATIVES AS FLT3 INHIBITORS | Biodol Therapeutics (FR) | 2025-07-09 | — | — | EP | claimed |
| EP-4565202-A1 | ALKALINE INTRAORAL PRODUCTS | EMPLICURE AB (publ) (SE) | 2025-06-11 | — | — | EP | claimed |
| US-12296043-B2 | Liquisoft capsules | PATHEON SOFTGELS INC. (US) | 2025-05-13 | — | — | US | claimed |
| US-5958452-A | SUSTAINED RELEASE FORMULATION COMPRISING EXTRUDED BLEND OF DRUG, HYDROPHOBIC MATERIAL, HYDROPHOBIC FUSIBLE CARRIER DIVIDED INTO UNIT DOSE | EURO-CELTIQUE, S.A. (LU) | 1999-09-28 | — | — | US | claimed |
| US-5654281-A | Inhibiting the development of tolerance to and/or dependence on an addictive substance | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 1997-08-05 | — | — | US | claimed |
| EP-0731694-A4 | — | — | 1996-10-02 | — | — | EP | claimed |
| EP-0731694-A1 | OPIOID FORMULATIONS FOR TREATING PAIN | Euroceltique S.A. (LU) | 1996-09-18 | — | — | EP | claimed |
| CN-1130352-A | Method for relieving pain by orally administering 24-hour sustained-release opioid dosage form capable of rapidly increasing initial blood concentration of patient | EURO CELTIQUE SA (LU) | 1996-09-04 | — | — | CN | claimed |
| WO-1995014460-A1 | OPIOID FORMULATIONS FOR TREATING PAIN | EURO-CELTIQUE S.A. (LU) | 1995-06-01 | — | — | WO | claimed |
| EP-0647448-A1 | Orally administrable opioid formulations having extended duration of effect | Euroceltique S.A. (LU) | 1995-04-12 | — | — | EP | claimed |
| EP-0608893-A1 | Inhibiting the development of tolerance to and/or dependence on an additive substance | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 1994-08-03 | — | — | EP | claimed |
| US-5187177-A | Method and a pharmaceutical preparation for treating pain | NOVO NORDISK A/S (DK) | 1993-02-16 | — | — | US | claimed |
| US-4126684-A | 4-AMINO-3-P-HALOPHENYLBUTYRIC ACIDS AND THEIR DERIVATIVES USED IN THE CONTROL OF NARCOTIC ABUSE | CIBA-GEIGY CORPORATION (US) | 1978-11-21 | — | — | US | claimed |